Drug intelligence / Profile preview

Clacier

Development stage: Phase 3
Modality: Small Molecules
Administration: Ophthalmic

Overview

Clacier is an ophthalmic nanoemulsion containing 0.05% Cyclosporine. It functions as a calcineurin inhibitor and an immunosuppressant. Primarily, it is used to enhance tear production in patients suffering from dry eye syndrome (keratoconjunctivitis sicca) due to ocular inflammation. Beyond its ophthalmic application, Clacier, through its active ingredient Cyclosporine, exerts broader immunosuppressive effects, making it valuable in preventing organ transplant rejection and managing various autoimmune disorders.

Brand names: Clacier

Targets

CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on Clacier.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clacier.

Explore the full profile